NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
Company's Unit - IX, an API intermediate facility situated at Sangareddy District, Telangana, has now been classified as Voluntary Action Indicated
If approved, TAK-003 has the potential to become an important dengue prevention option for healthcare providers
NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.
Doubling of median overall survival seen in QuANTUM-First results presented at EHA Presidential Symposium
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Active pharmaceutical ingredients revenue for the quarter was at Rs 913 crore
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Avillion announces expansion of partnership with AstraZeneca on PT027 and will fund and execute a new Phase 3b study
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
